Repurposing hydrochlorothiazide (HCTZ) for colorectal cancer: a retrospective and single center study
BackgroundAnti-hypertensive drugs have been reported to demonstrate anti-inflammatory and anti-angiogenic effects. This study aims to investigate the association between anti-hypertensive drugs and the prognosis of colorectal cancer (CRC) patients.MethodsClinical data of 1134 CRC patients with hyper...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1449062/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850077154201567232 |
|---|---|
| author | Dominic Chi-Chung Foo Jiaxi Li Zheng Huang Siming Sui Ryan Wai-Yan Sin Abraham Tak Ka Man Wai-Lun Law Lui Ng |
| author_facet | Dominic Chi-Chung Foo Jiaxi Li Zheng Huang Siming Sui Ryan Wai-Yan Sin Abraham Tak Ka Man Wai-Lun Law Lui Ng |
| author_sort | Dominic Chi-Chung Foo |
| collection | DOAJ |
| description | BackgroundAnti-hypertensive drugs have been reported to demonstrate anti-inflammatory and anti-angiogenic effects. This study aims to investigate the association between anti-hypertensive drugs and the prognosis of colorectal cancer (CRC) patients.MethodsClinical data of 1134 CRC patients with hypertensions and the prescription of anti-hypertensive drugs who had undergone curative surgery in our hospital between 2005 and 2015 were retrieved. Their survival data and immune cell population in circulatory blood were compared among different types of anti-hypertensive drugs and overall CRC patients.ResultsThe 5-year overall survival for the antihypertensives-treated patients (65.2%) was higher than the CRC patients in Hong Kong (58.2%). Hydrochlorothiazide (HCTZ) group showed the best prognosis (79.1%) among different antihypertensive drug, particularly for advance stage or elderly patients, which are poor prognostic factors for overall CRC patients, demonstrated an obviously improved prognosis upon HCTZ treatment. Moreover, our data showed the recurrence rate was significantly lower for HCTZ group (18.3%) compared to non-HCTZ group (26.8%) and the reported rate (31%) of CRC patients in Hong Kong. Finally, patients with a lower pre-operative basophil level showed better overall and disease-free survival following HCTZ treatment.ConclusionThis study demonstrated the association of HCTZ treatment with a better prognosis of CRC patients. |
| format | Article |
| id | doaj-art-168d2a2c73cd45fca30093685e848fc3 |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-168d2a2c73cd45fca30093685e848fc32025-08-20T02:45:52ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-02-011610.3389/fphar.2025.14490621449062Repurposing hydrochlorothiazide (HCTZ) for colorectal cancer: a retrospective and single center studyDominic Chi-Chung FooJiaxi LiZheng HuangSiming SuiRyan Wai-Yan SinAbraham Tak Ka ManWai-Lun LawLui NgBackgroundAnti-hypertensive drugs have been reported to demonstrate anti-inflammatory and anti-angiogenic effects. This study aims to investigate the association between anti-hypertensive drugs and the prognosis of colorectal cancer (CRC) patients.MethodsClinical data of 1134 CRC patients with hypertensions and the prescription of anti-hypertensive drugs who had undergone curative surgery in our hospital between 2005 and 2015 were retrieved. Their survival data and immune cell population in circulatory blood were compared among different types of anti-hypertensive drugs and overall CRC patients.ResultsThe 5-year overall survival for the antihypertensives-treated patients (65.2%) was higher than the CRC patients in Hong Kong (58.2%). Hydrochlorothiazide (HCTZ) group showed the best prognosis (79.1%) among different antihypertensive drug, particularly for advance stage or elderly patients, which are poor prognostic factors for overall CRC patients, demonstrated an obviously improved prognosis upon HCTZ treatment. Moreover, our data showed the recurrence rate was significantly lower for HCTZ group (18.3%) compared to non-HCTZ group (26.8%) and the reported rate (31%) of CRC patients in Hong Kong. Finally, patients with a lower pre-operative basophil level showed better overall and disease-free survival following HCTZ treatment.ConclusionThis study demonstrated the association of HCTZ treatment with a better prognosis of CRC patients.https://www.frontiersin.org/articles/10.3389/fphar.2025.1449062/fullcolorectal cancerdrug repurposingantihypertensive drugshydrochlorothiazidebasophilprognosis |
| spellingShingle | Dominic Chi-Chung Foo Jiaxi Li Zheng Huang Siming Sui Ryan Wai-Yan Sin Abraham Tak Ka Man Wai-Lun Law Lui Ng Repurposing hydrochlorothiazide (HCTZ) for colorectal cancer: a retrospective and single center study Frontiers in Pharmacology colorectal cancer drug repurposing antihypertensive drugs hydrochlorothiazide basophil prognosis |
| title | Repurposing hydrochlorothiazide (HCTZ) for colorectal cancer: a retrospective and single center study |
| title_full | Repurposing hydrochlorothiazide (HCTZ) for colorectal cancer: a retrospective and single center study |
| title_fullStr | Repurposing hydrochlorothiazide (HCTZ) for colorectal cancer: a retrospective and single center study |
| title_full_unstemmed | Repurposing hydrochlorothiazide (HCTZ) for colorectal cancer: a retrospective and single center study |
| title_short | Repurposing hydrochlorothiazide (HCTZ) for colorectal cancer: a retrospective and single center study |
| title_sort | repurposing hydrochlorothiazide hctz for colorectal cancer a retrospective and single center study |
| topic | colorectal cancer drug repurposing antihypertensive drugs hydrochlorothiazide basophil prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1449062/full |
| work_keys_str_mv | AT dominicchichungfoo repurposinghydrochlorothiazidehctzforcolorectalcanceraretrospectiveandsinglecenterstudy AT jiaxili repurposinghydrochlorothiazidehctzforcolorectalcanceraretrospectiveandsinglecenterstudy AT zhenghuang repurposinghydrochlorothiazidehctzforcolorectalcanceraretrospectiveandsinglecenterstudy AT simingsui repurposinghydrochlorothiazidehctzforcolorectalcanceraretrospectiveandsinglecenterstudy AT ryanwaiyansin repurposinghydrochlorothiazidehctzforcolorectalcanceraretrospectiveandsinglecenterstudy AT abrahamtakkaman repurposinghydrochlorothiazidehctzforcolorectalcanceraretrospectiveandsinglecenterstudy AT wailunlaw repurposinghydrochlorothiazidehctzforcolorectalcanceraretrospectiveandsinglecenterstudy AT luing repurposinghydrochlorothiazidehctzforcolorectalcanceraretrospectiveandsinglecenterstudy |